论文部分内容阅读
目的分析探讨舒利迭联合思力华治疗稳定期慢性阻塞性肺疾病的临床疗效。方法将64例稳定期COPD患者随机分为观察组和对照组各32例,对照组患者仅给予吸入舒利迭50μg/2500μg/次,2次/d,观察组患者给予吸入舒利迭和思力华;治疗3个月后判定两组临床疗效及不良反应发生情况。结果观察组FEVl/FVC以及FEV1占预计值百分比较对照组明显提高,临床症状体征亦明显改善(P<0.05);两组患者均无严重不良反应发生。结论舒利迭联合思力华治疗稳定期慢性阻塞性肺疾病患者可以明显改善临床症状及肺功能,且不良反应少,值得临床推广应用。
Objective To investigate the clinical efficacy of seretide combined with silihua in the treatment of stable chronic obstructive pulmonary disease. Methods Sixty-four patients with stable COPD were randomly divided into two groups: observation group and control group, 32 cases in each group. Patients in the control group were given 50 μg / 2500 μg twice daily, and the patients in the observation group were given inhaled Seretide Lihua; 3 months after treatment to determine the clinical efficacy and adverse reactions in both groups. Results The percentages of FEV1 / FVC and FEV1 in the observation group were significantly higher than those in the control group, and the clinical symptoms and signs were also significantly improved (P <0.05). No serious adverse reactions occurred in both groups. Conclusion The combination of sulpiride and SiLihua in patients with stable chronic obstructive pulmonary disease can significantly improve the clinical symptoms and pulmonary function with less adverse reactions and is worthy of clinical application.